Trial intelligence / Profile preview

Phase II study of lazertinib 160 mg daily in EGFR T790M-mutant non-small cell lung cancer

KCT0008332Phase 2Recruiting

Sponsor

Yuhan

Start

Jan 2023

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1